Olanzapine + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Depression, Bipolar

Conditions

Depression, Bipolar

Trial Timeline

Aug 1, 2007 โ†’ Jul 1, 2010

About Olanzapine + Placebo

Olanzapine + Placebo is a phase 3 stage product being developed by Eli Lilly for Depression, Bipolar. The current trial status is completed. This product is registered under clinical trial identifier NCT00510146. Target conditions include Depression, Bipolar.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (6)

NCT IDPhaseStatus
NCT00520507ApprovedCompleted
NCT00510146Phase 3Completed
NCT00091650Phase 3Completed
NCT00051298Phase 3Completed
NCT00050206ApprovedCompleted
NCT00592930ApprovedCompleted

Competing Products

20 competing products in Depression, Bipolar

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
QuetiapineAstellas PharmaPre-clinical
23
duloxetine + escitalopram + placeboEli LillyPhase 3
77
duloxetineEli LillyApproved
85
Duloxetine HydrochlorideEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
DuloxetineEli LillyApproved
85
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)Eli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
duloxetine + fluoxetine + citalopram + paroxetine + sertralineEli LillyApproved
85
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
77
duloxetine + duloxetineEli LillyPre-clinical
23
olanzapine + ziprasidoneEli LillyApproved
85
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
85
Drug treatment with CymbaltaEli LillyApproved
85
DuloxetineEli LillyApproved
85
DuloxetineEli LillyApproved
85